Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2010. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than comprehensive financial performance.
Material Changes
Following a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan (notionally held in GSK Ordinary share ADRs), an increase in the notional allocation of Ordinary share ADRs occurred on October 28, 2010. The transaction price was $39.38 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Date: October 28, 2010 (Notification date: November 3, 2010).
- Transaction Price: $39.38 per ADR.
- Participants: Dr M M Slaoui (7 ADRs), Mrs C E Bruck Slaoui (1 ADR), Mr E J Gray (18 ADRs), Mr W C Louv (12 ADRs), Dr D Pulman (22 ADRs), Ms D Connelly (1 ADR).
- Context: The increase resulted from a re-valuation of the cash element within the US Retirement Savings Plan.